**Modelling benefits, costs and affordability of a novel gene therapy in hemophilia A**

*Renske M.T. ten Ham1,2,3\*, Simon Walker2, Marta Soares2, Geert W. J. Frederix1,3, Frank W.G. Leebeek4, Kathelijn Fischer5, Michiel Coppens6, Stephen Palmer2*

1 Division of Pharmacoepidemiology and Clinical Pharmacology of the Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht, The Netherlands,

2 Centre for Health Economics, University of York, York, United Kingdom,

3 Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University,

4 Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands,

5 Division Internal Medicine and Dermatology, Van Creveldkliniek, University Medical Center Utrecht,

6 Department of Vascular Medicine, Amsterdam University Medical Centres, Amsterdam, the Netherlands.

\*Corresponding author: [R.M.T.tenHam-2@UMCUtrecht.nl](mailto:R.M.T.tenHam-2@UMCUtrecht.nl).

**SUPPLEMENTAL MATERIALS**

**Figure S1: Cost-effectiveness acceptability curve showing pairwise comparison.** Table

Description automatically generated

Valrox - valoctocogene roxaparvovec (Roctavian®). WTP – Willingness to pay threshold.

QALY – Quality adjusted life year. inc – incremental.

**Figure S2: Deterministic sensitivity analysis valrox compared to prophylactic FVIII**. Listed are the parameters displaying largest spread of incremental QALYs [A] and incremental costs [B].

Table

Description automatically generated Table

Description automatically generated

B

A

Valrox - valoctocogene roxaparvovec (Roctavian®). QALY – Quality adjusted life year.

**Figure S3: Deterministic sensitivity analysis valrox compared to prophylactic emicizumab.** Listed are the parameters displaying largest spread of incremental QALYs [A] and incremental costs [B].

Table

Description automatically generated

A

Table

Description automatically generated

B

Valrox - valoctocogene roxaparvovec (Roctavian®). QALY – Quality adjusted life year.

**Figure 4: Results of the probabilistic sensitivity analysis in a cost-effectiveness plane** (1000 iterations)**.** [A] valrox compared to FVIII prophylaxis and [B] valrox compared to emicizumab*.*

Chart, scatter chart

Description automatically generated

A

Chart, scatter chart

Description automatically generated

B

*ICER - Incremental cost-effectiveness ration. Valrox -* valoctocogene roxaparvovec (Roctavian®). WTP – Willingness to pay threshold.